MARKET

CERS

CERS

Cerus Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.19
+0.19
+2.71%
After Hours: 7.19 0 0.00% 16:02 12/04 EST
OPEN
7.03
PREV CLOSE
7.00
HIGH
7.30
LOW
7.03
VOLUME
2.03M
TURNOVER
--
52 WEEK HIGH
7.94
52 WEEK LOW
2.710
MARKET CAP
1.20B
P/E (TTM)
-18.0517
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Apheresis Market Is Expected To Reach USD 2.5 Billion By 2020, Growing At A CAGR Of 11.2% During The Forecast Period 2015-2020
Japan, Japan, Wed, 02 Dec 2020 14:35:42 / Comserve Inc. / -- The market is mainly driven by the rising incidences of blood disorders and chronic diseases, increasing demand for source plasma from biopharmaceutical companies, and increasing demand for blood for transfusion in surgical procedures
Comserve · 2d ago
Cerus (CERS) Is Up 2.47% in One Week: What You Should Know
Zacks · 4d ago
FDA OKs new use of Cerus Intercept system, shares up 7%
The FDA approves Cerus' (CERS) Intercept Blood System for cryoprecipitation, specifically for producing pathogen-reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen
Seekingalpha · 4d ago
Cerus Corporation Announces FDA Approval For INTERCEPT Blood System For Cryoprecipitation
Cerus Corporation (NASDAQ:CERS) today announced that the US Food and Drug Administration (FDA) has granted approval of the INTERCEPT Blood System for Cryoprecipitation. The system is used to produce Pathogen Reduced
Benzinga · 4d ago
All You Need to Know About Cerus (CERS) Rating Upgrade to Buy
Cerus (CERS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks · 11/20 17:00
Cerus Corporation to Participate in Upcoming Virtual Investor Conferences
Cerus Corporation (Nasdaq: CERS) announced today that William 'Obi' Greenman, Cerus' president and chief executive officer, and Kevin D. Green, Cerus' chief financial officer, are scheduled to participate in two conferences:
BusinessWire · 11/12 10:30
Cerus Corporation (NASDAQ:CERS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
It's been a sad week for Cerus Corporation (NASDAQ:CERS), who've watched their investment drop 17% to US$5.25 in the...
Simply Wall St. · 11/01 12:59
Cerus Corp.to Host Earnings Call
ACCESSWIRE · 10/29 19:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CERS. Analyze the recent business situations of Cerus Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CERS stock price target is 9.30 with a high estimate of 10.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 242
Institutional Holdings: 152.17M
% Owned: 91.04%
Shares Outstanding: 167.14M
TypeInstitutionsShares
Increased
52
11.48M
New
43
-1.60M
Decreased
51
8.15M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.47%
Healthcare Equipment & Supplies
+1.26%
Key Executives
Chairman/Director
Daniel Swisher
Chief Executive Officer/President/Director
William Greenman
Chief Financial Officer/Vice President - Finance
Kevin Green
Chief Operating Officer
Vivek Jayaraman
Senior Vice President
Carol Moore
Chief Scientific Officer
Laurence Corash
Other
Richard Benjamin
Other
Chrystal Menard
Independent Director
Timothy Anderson
Independent Director
Eric Bjerkholt
Independent Director
Timothy Moore
Independent Director
Jami Nachtsheim
Independent Director
Gail Schulze
Independent Director
Frank Witney
Independent Director
Franklin Witney
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CERS
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Cerus Corporation stock information, including NASDAQ:CERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CERS stock methods without spending real money on the virtual paper trading platform.